STING1 and neoplasm: Systemic administration with dNAc combined with NIR‐II photoactivation significantly decreased primary tumor growth, suppressed distant metastasis, and inhibited liver and lung metastasis in a murine model.[114e] These results highlight the immense therapeutic potential of combining STING agonist‐based immunotherapy with PTT.